Evaluation of LMI1195, a novel 18F-labeled cardiac neuronal PET imaging agent, in cells and animal models

Circulation: Cardiovascular Imaging

Volumn 4, Issue 4, 2011, Pages 435-443

  Yu, Ming ^a   Bozek, Jody ^a   Lamoy, Melanie ^a   Guaraldi, Mary ^a   Silva, Paula ^a   Kagan, Mikhail ^a   Yalamanchili, Padmaja ^a   Onthank, David ^a   Mistry, Mahesh ^a   Lazewatsky, Joel ^a   Broekema, Matthias ^a   Radeke, Heike ^a   Purohit, Ajay ^a   Cdebaca, Michael ^a   Azure, Michael ^a   Cesati, Richard ^a   Casebier, David ^a   Robinson, Simon P ^a  

^a A Subsidiary of Lantheus Holdings   (United States)

Author keywords

18F; Cardiac neuronal imaging; Heart failure; Norepinephrine transporter; Positron emission tomography

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; DESIPRAMINE; FLUORINE 18; FLURPIRIDAZ F 18; N [3 BROMO 4 (3 [18F]FLUORO PROPOXY)BENZYL]GUANIDINE; NORADRENALIN; NORADRENALIN TRANSPORTER; OXIDOPAMINE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; FLUORINE; FLUOROBENZENE; GUANIDINE DERIVATIVE; N (3 BROMO 4 (3 (18F)FLUORO PROPOXY)BENZYL)GUANIDINE; N-(3-BROMO-4-(3-(18F)FLUORO-PROPOXY)BENZYL)GUANIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING ASSAY; CARDIAC IMAGING; CELL MEMBRANE; DENERVATION; DRUG UPTAKE; EXPERIMENTAL RABBIT; HEART; HEART FAILURE; HEART MUSCLE; HUMAN; HUMAN CELL; LIVER; LUNG; MALE; NEUROBLASTOMA CELL; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIMATE; PRIORITY JOURNAL; RADIOACTIVITY; RAT; ANIMAL; DISEASE MODEL; EVALUATION; HALF LIFE TIME; IMAGE PROCESSING; MACACA FASCICULARIS; METABOLISM; METHODOLOGY; NEUROBLASTOMA; RABBIT; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; SPRAGUE DAWLEY RAT; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; DENERVATION; DISEASE MODELS, ANIMAL; FLUORINE RADIOISOTOPES; FLUOROBENZENES; GUANIDINES; HALF-LIFE; HEART FAILURE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MACACA FASCICULARIS; MALE; NEUROBLASTOMA; POSITRON-EMISSION TOMOGRAPHY; RABBITS; RADIOPHARMACEUTICALS; RATS; RATS, SPRAGUE-DAWLEY; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION;

EID: 80053337341     PISSN: 19419651     EISSN: 19420080     Source Type: Journal    
DOI: 10.1161/CIRCIMAGING.110.962126     Document Type: Article

References (38)

1. Eisenhofer G, Friberg P, Rundqvist B, Quyyumi AA, Lambert G, Kaye DM, Kopin IJ, Goldstein DS, Esler MD. Cardiac sympathetic nerve function in congestive heart failure. Circulation. 1996;93:1667-1676. (Pubitemid 26131343)
2. Bohm M, La Rosee K, Schwinger RH, Erdmann E. Evidence for reduction of norepinephrine uptake sites in the failing human heart. J Am Coll Cardiol. 1995;25:146-153.
3. Bengel FM, Schwaiger M. Assessment of cardiac sympathetic neuronal function using PET imaging. J Nucl Cardiol. 2004;11:603-616. (Pubitemid 39341805)
4. Travin MI. Cardiac neuronal imaging at the edge of clinical application. Cardiol Clin. 2009;27:311-327.
5. Henneman MM, Bengel FM, van der Wall EE, Knuuti J, Bax JJ. Cardiac neuronal imaging: application in the evaluation of cardiac disease. J Nucl Cardiol. 2008;15:442-455.
6. Merlet P, Valette H, Dubois-Rande JL, Moyse D, Duboc D, Dove P, Bourguignon MH, Benvenuti C, Duval AM, Agostini D. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med. 1992;33:471-477.
7. Cohen-Solal A, Esanu Y, Logeart D, Pessione F, Dubois C, Dreyfus G, Gourgon R, Merlet P. Cardiac metaiodobenzylguanidine uptake in patients with moderate chronic heart failure: relationship with peak oxygen uptake and prognosis. J Am Coll Cardiol. 1999;33:759-766.
8. Agostini D, Verberne HJ, Burchert W, Knuuti J, Povinec P, Sambuceti G, Unlu M, Estorch M, Banerjee G, Jacobson AF. I-123-mIBG myocardial imaging for assessment of risk for a major cardiac event in heart failure patients: insights from a retrospective European multicenter study. Eur J Nucl Med Mol Imaging. 2008;35:535-546.
9. Pietila M, Malminiemi K, Ukkonen H, Saraste M, Nagren K, Lehikoinen P, Voipio-Pulkki LM. Reduced myocardial carbon-11 hydroxyephedrine retention is associated with poor prognosis in chronic heart failure. Eur J Nucl Med. 2001;28:373-376.
10. Agostini D, Belin A, Amar MH, Darlas Y, Hamon M, Grollier G, Potier JC, Bouvard G. Improvement of cardiac neuronal function after carvedilol treatment in dilated cardiomyopathy: a 123I-MIBG scintigraphic study. J Nucl Med. 2000;41:845-851. (Pubitemid 30266029)
11. Nakata T, Wakabayashi T, Kyuma M, Takahashi T, Tsuchihashi K, Shimamoto K. Cardiac metaiodobenzylguanidine activity can predict the long-term efficacy of angiotensin-converting enzyme inhibitors and/or beta-adrenoceptor blockers in patients with heart failure. Eur J Nucl Med Mol Imaging. 2005;32:186-194. (Pubitemid 40248490)
12. Bengel FM, Ueberfuhr P, Schiepel N, Nekolla SG, Reichart B, Schwaiger M. Effect of sympathetic reinnervation on cardiac performance after heart transplantation. N Engl J Med. 2001;345:731-738.
13. Jacobson AF, Senior R, Cerqueira MD, Wong ND, Thomas GS, Lopez VA, Agostini D, Weiland F, Chandna H, Narula J. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure: results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol. 2010;55: 2212-2221.
14. Carrio I. Cardiac neurotransmission imaging. J Nucl Med. 2001;42: 1062-1076. (Pubitemid 32595307)
15. Gropler RJ, Soto P. Recent advances in cardiac positron emission tomography in the clinical management of the cardiac patient. Curr Cardiol Rep. 2004;6:20-26. (Pubitemid 38915015)
16. Anzai T, Yoshikawa T, Baba A, Nishimura H, Shiraki H, Nagami K, Suzuki M, Wainai Y, Ogawa S. Myocardial sympathetic denervation prevents chamber-specific alteration of beta-adrenergic transmembrane signaling in rabbits with heart failure. J Am Coll Cardiol. 1996;28: 1314-1322. (Pubitemid 26377011)
17. Inoko M, Kihara Y, Morii I, Fujiwara H, Sasayama S. Transition from compensatory hypertrophy to dilated, failing left ventricles in Dahl saltsensitive rats. Am J Physiol. 1994;267:H2471-H2482.
18. Bozek J, Silva P, Lamoy M, Azure M, Radeke H, Robinson S, Yu M. Heart Failure Imaging in the rat with LMI1195, a new PET cardiac neuronal imaging agent. Circulation. 2009;120:S362.
19. Yu M, Guaraldi MT, Mistry M, Kagan M, McDonald JL, Drew K, Radeke H, Azure M, Purohit A, Casebier DS, Robinson SP. BMS- 747158-02: a novel PET myocardial perfusion imaging agent. J Nucl Cardiol. 2007;14:789-798. (Pubitemid 350082572)
20. Nekolla SG, Reder S, Saraste A, Higuchi T, Dzewas G, Preissel A, Huisman M, Poethko T, Schuster T, Yu M, Robinson S, Casebier D, Henke J, Wester HJ, Schwaiger M. Evaluation of the novel myocardial perfusion positron-emission tomography tracer 18F-BMS-747158-02: comparison to 13N-ammonia and validation with microspheres in a pig model. Circulation. 2009;119:2333-2342.
21. Larson SG. Ontogenetic and interspecific organ weight allometry in Old World monkeys. Am J Phys Anthropol. 1984;64:59-67. (Pubitemid 14079169)
22. Liang CS, Fan TH, Sullebarger JT, Sakamoto S. Decreased adrenergic neuronal uptake activity in experimental right heart failure: a chamber-specific contributor to beta-adrenoceptor downregulation. J Clin Invest. 1989;84:1267-1275. (Pubitemid 19247600)
23. Backs J, Haunstetter A, Gerber SH, Metz J, Borst MM, Strasser RH, Kubler W, Haass M. The neuronal norepinephrine transporter in experimental heart failure: evidence for a posttranscriptional downregulation. J Mol Cell Cardiol. 2001;33:461-472. (Pubitemid 32539003)
24. Buss SJ, Backs J, Kreusser MM, Hardt SE, Maser-Gluth C, Katus HA, Haass M. Spironolactone preserves cardiac norepinephrine reuptake in salt-sensitive Dahl rats. Endocrinology. 2006;147:2526-2534.
25. Beau SL, Saffitz JE. Transmural heterogeneity of norepinephrine uptake in failing human hearts. J Am Coll Cardiol. 1994;23:579-585. (Pubitemid 24074932)
26. Brush JE Jr, Eisenhofer G, Garty M, Stull R, Maron BJ, Cannon RO III, Panza JA, Epstein SE, Goldstein DS. Cardiac norepinephrine kinetics in hypertrophic cardiomyopathy. Circulation. 1989;79:836-844. (Pubitemid 19100543)
27. Munch G, Rosport K, Bultmann A, Baumgartner C, Li Z, Laacke L, Ungerer M. Cardiac overexpression of the norepinephrine transporter uptake-1 results in marked improvement of heart failure. Circ Res. 2005; 97:928-936. (Pubitemid 41552679)
28. Bax JJ, Kraft O, Buxton AE, Fjeld JG, Parizek P, Agostini D, Knuuti J, Flotats A, Arrighi J, Muxi A, Alibelli MJ, Banerjee G, Jacobson AF. 123 I-mIBG scintigraphy to predict inducibility of ventricular arrhythmias on cardiac electrophysiology testing: a prospective multicenter pilot study. Circ Cardiovasc Imaging. 2008;1:131-140.
29. Raffel DM, Jung YW, Gildersleeve DL, Sherman PS, Moskwa JJ, Tluczek LJ, Chen W. Radiolabeled phenethylguanidines: novel imaging agents for cardiac sympathetic neurons and adrenergic tumors. J Med Chem. 2007;50:2078-2088. (Pubitemid 46683061)
30. Nozawa T, Igawa A, Yoshida N, Maeda M, Inoue M, Yamamura Y, Asanoi H, Inoue H. Dual-tracer assessment of coupling between cardiac sympathetic neuronal function and downregulation of beta-receptors during development of hypertensive heart failure of rats. Circulation. 1998;97:2359-2367. (Pubitemid 28280391)
31. Boogers MJ, Borleffs CJ, Henneman MM, Van Bommel RJ, van Ramshorst J, Boersma E, Dibbets-Schneider P, Stokkel MP, van der Wall EE, Schalij MJ, Bax JJ. Cardiac sympathetic denervation assessed with 123- iodine metaiodobenzylguanidine imaging predicts ventricular arrhythmias in implantable cardioverter-defibrillator patients. J Am Coll Cardiol. 2010;55:2769-2777.
32. Sasano T, Abraham MR, Chang KC, Ashikaga H, Mills KJ, Holt DP, Hilton J, Nekolla SG, Dong J, Lardo AC, Halperin H, Dannals RF, Marban E, Bengel FM. Abnormal sympathetic innervation of viable myocardium and the substrate of ventricular tachycardia after myocardial infarction. J Am Coll Cardiol. 2008;51:2266-2275. (Pubitemid 351754990)
33. Hartmann F, Ziegler S, Nekolla S, Hadamitzky M, Seyfarth M, Richardt G, Schwaiger M. Regional patterns of myocardial sympathetic denervation in dilated cardiomyopathy: an analysis using carbon-11 hydroxyephedrine and positron emission tomography. Heart. 1999;81: 262-270. (Pubitemid 29116337)
34. Goldstein DS, Katzper M, Linares O, Kopin IJ. Kinetic model for the fate of 6-[18F]fluorodopamine in the human heart: a novel means to examine cardiac sympathetic neuronal function. Naunyn Schmiedebergs Arch Pharmacol. 2002;365:38-49. (Pubitemid 34045238)
35. Berry CR, Garg PK, Zalutsky MR, Coleman RE, DeGrado TR. Uptake and retention kinetics of para-fluorine-18-fluorobenzylguanidine in isolated rat heart. J Nucl Med. 1996;37:2011-2016. (Pubitemid 26428373)
36. Vaidyanathan G, Affleck DJ, Zalutsky MR. (4-[18F]fluoro-3- iodobenzyl)guanidine, a potential MIBG analogue for positron emission tomography. J Med Chem. 1994;37:3655-3662.
37. Winslow RD, Pinney S, Fuster V. Impact of implantable- cardioverterdefibrillator trials on clinical management of patients with heart failure. Nat Clin Pract Cardiovasc Med. 2006;3:86-93. (Pubitemid 43203377)
38. Nishioka SA, Martinelli FM, Brandao SC, Giorgi MC, Vieira ML, Costa R, Mathias W, Meneghetti JC. Cardiac sympathetic activity pre and post resynchronization therapy evaluated by 123I-MIBG myocardial scintigraphy. J Nucl Cardiol. 2007;14:852-859. (Pubitemid 350082581)